FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and optimal dose of PF-04136309 when given with
combination chemotherapy (FOLFIRINOX; 5-fluorouracil, leucovorin, irinotecan, oxaliplatin) in
treating patients with locally advanced or borderline resectable pancreatic cancer. These
patients are not candidates for surgical resection which is the most effective treatment for
pancreatic cancer. Giving PF-04136309 together with FOLFIRINOX may shrink pancreatic tumors
in some patients so that surgery becomes an option